Dynamic quotes: Off
|
ETFs with ABT as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 6.03% | iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE) | +18.79 (22.37%) |
| 5.89% | Select Sector SPDR Fund - Health Care (XLV) | +2.17 (5.63%) |
| 5.62% | Vanguard Health Care ETF (VHT) | +17.88 (25.26%) |
| 5.04% | PowerShares Dynamic Pharmaceuticals (PJP) | +9.26 (27.19%) |
| 4.62% | Merrill Lynch Pharmaceutical HOLDRS (PPH) | +8.03 (20.41%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products. FINANCIAL INFORMATION RELATING TO INDUSTRY SEGMENTS, GEOGRAPHIC AREAS, AND CLASSES OF SIMILAR PRODUCTS Incorporated herein by reference is Note 6 entitled "Segment and Geographic Area Information" of the Notes to Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data" and the sales information related to HUMIRA® included in "Financial Review." NARRATIVE DESCRIPTION OF BUSINESS Through December 31, 2012, Abbott had five reportable revenue segments: Proprietary Pharmaceutical Products, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $5.07 |
| Quarterly EPS Est: | 0.44 |
| PEG Ratio: | 1.60 |
|
Mean Recommendation: View Summary / View All |
2.05 |
Data is provided by Zacks Investment Research